[225Ac]Ac-DOTATATE / Sinotau Pharma - LARVOL DELTA

IIT-XT024-1-01: A Phase I Study to Assess the Safety and Efficacy of [225Ac]Ac-DOTATATE in Patients With SSTR+ GEP-Nens (clinicaltrials.gov) - P1 | N=36 | Recruiting | Sponsor: Peking University Cancer Hospital & Institute | N=24 ➔ 36

Enrollment change • Endocrine Cancer • Neuroendocrine Carcinoma • Neuroendocrine Tumor • Oncology • Solid Tumor

Modeling the effect of daughter migration on dosimetry estimates for [225Ac]Ac-DOTATATE. (PubMed, Int J Radiat Oncol Biol Phys) - "When performing dosimetry for [225Ac]Ac-DOTATATE, our study found that if daughter migration is ignored, the kidney dose is underestimated by approximately 10%, and the tumor dose is overestimated by approximately 23%. For accurate dosimetry, daughter biokinetics should be considered."

Journal • Endocrine Cancer • Neuroendocrine Tumor • Oncology • Solid Tumor

IIT-XT024-1-01: A Phase I Study to Assess the Safety and Efficacy of [225Ac]Ac-DOTATATE in Patients with SSTR+ GEP-Nets (clinicaltrials.gov) - P1 | N=24 | Recruiting | Sponsor: Peking University Cancer Hospital & Institute | Not yet recruiting ➔ Recruiting | Initiation date: Jan 2025 ➔ Sep 2024 | Trial primary completion date: Jul 2025 ➔ Dec 2025

Enrollment open • Trial initiation date • Trial primary completion date • Endocrine Cancer • Neuroendocrine Tumor • Oncology • Solid Tumor

Significant response to [225Ac]Ac-DOTATATE therapy in a patient with small cell lung cancer. (PubMed, Eur J Nucl Med Mol Imaging) - No abstract available

Journal • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

IIT-XT024-1-01: A Phase I Study to Assess the Safety and Efficacy of [225Ac]Ac-DOTATATE in Patients with SSTR+ GEP-Nets (clinicaltrials.gov) - P1 | N=24 | Not yet recruiting | Sponsor: Peking University Cancer Hospital & Institute

Metastases • New P1 trial • Endocrine Cancer • Neuroendocrine Tumor • Oncology • Solid Tumor